Mucopolysaccharidosis Type IVA Clinical Trials

Mucopolysaccharidosis Type IVA is caused by mutations in the GALNS gene, leading to deficiency of the enzyme N-acetylgalactosamine-6-sulfatase. Without this enzyme, the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate accumulate in lysosomes throughout the body, particularly in cartilage and bone. This accumulation disrupts normal skeletal development and causes progressive damage to connective tissues, heart valves, corneas, and the respiratory system.

The most common symptoms of Mucopolysaccharidosis Type IVA include Short stature and growth restriction beginning in early childhood, Kyphoscoliosis and progressive spinal curvature, Knock-knee deformity (genu valgum) causing difficulty walking, Barrel chest (pectus carinatum) and rib flaring, Progressive joint pain, stiffness, and laxity, among others. Estimated at 1 in 200,000 to 300,000 people for MPS IV overall; the exact prevalence is unknown. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Mucopolysaccharidosis Type IVA from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials for MPS IVA are exploring next-generation enzyme replacement approaches, gene therapy, and combination strategies to improve on the current standard of care with Vimizim. Because skeletal damage is progressive and partly irreversible, earlier treatment generally leads to better outcomes, making early diagnosis through newborn screening a research priority.

Yes. As of October 14, 2026, 1 FDA-approved medicine has a current label that names Mucopolysaccharidosis Type IVA: Vimizim (elosulfase alfa). Corticosteroids and immune globulins count once each.

Mucopolysaccharidosis Type IVA is caused by variants in the GALNS gene. MPS IVA is GALNS; the clinically similar MPS IVB is caused by GLB1.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. Estimated at 1 in 200,000 to 300,000 people for MPS IV overall; the exact prevalence is unknown. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Mucopolysaccharidosis Type IVA looks at the GALNS gene. MPS IVA is GALNS; the clinically similar MPS IVB is caused by GLB1.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Mucopolysaccharidosis Type IVA clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Mucopolysaccharidosis Type IVA clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.